FTC supports Bystolic pay-for-delay case

The Federal Trade Commission has backed private plaintiffs seeking the reinstatement of their claims that an AbbVie subsidiary illegally delayed generic competition for its hypertension drug.

Unlock unlimited access to all Global Competition Review content